Who are intravenous levetireacetam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Keppra, Topiramate monotherapy, Oral levetiracetam, Lacosamide - rapid titration 1, Low dose levetiracetam, Low dose zonisamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-levetireacetam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

intravenous levetireacetam — Competitive Intelligence Brief

intravenous levetireacetam (intravenous levetireacetam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic agent. Area: Neurology.

marketed Antiepileptic agent SV2A (synaptic vesicle protein 2A) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

intravenous levetireacetam (intravenous levetireacetam) — ayesha tariq. Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intravenous levetireacetam TARGET	intravenous levetireacetam	ayesha tariq	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Keppra	levetiracetam	Generic (originally UCB Pharma)	marketed	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
Topiramate monotherapy	Topiramate monotherapy	Johnson & Johnson Taiwan Ltd	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
Oral levetiracetam	Oral levetiracetam	Children's Hospital of Fudan University	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Lacosamide - rapid titration 1	Lacosamide - rapid titration 1	Seoul National University Hospital	marketed	Antiepileptic agent (sodium channel modulator)	Voltage-gated sodium channels (slow inactivation enhancer)
Low dose levetiracetam	Low dose levetiracetam	Richard H. Haas	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Low dose zonisamide	Low dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase

Recent regulatory actions (last 90 days)

2026-04-08 — Keppra · FDA · approved · US · Generic (originally UCB Pharma)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-03 — Keppra · 8163306 · Formulation · US
2027-10-31 — Keppra · 8431156 · Formulation · US
2027-10-31 — Keppra · 8470367 · Formulation · US
2028-09-17 — Keppra · 7858122 · Formulation · US
2031-06-07 — Keppra · 8802142 · Formulation · US
2031-12-07 — Keppra · 8802142*PED · Compound · US
2034-03-14 — Keppra · 11160786 · Formulation · US
2034-03-14 — Keppra · 9669009 · Method of Use · US
2034-03-14 — Keppra · 9339489 · Formulation · US

Sponsor landscape (Antiepileptic agent class)

Children's Hospital of Fudan University · 1 drug in this class
Generic (originally UCB Pharma) · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Mario Negri Institute for Pharmacological Research · 1 drug in this class
Richard H. Haas · 1 drug in this class
ayesha tariq · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). intravenous levetireacetam — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-levetireacetam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab